Take Solutions Ltd Q2/H1 FY25 – When Clinical Trials Meet Corporate Comedy: Loss ₹697 Mn, Promoter Drama, Auditor Exit, and a P/E of 114 That Deserves Its Own Netflix Series

1. At a Glance

Ladies and gentlemen, presenting Take Solutions Ltd, the life sciences and support services specialist that’s currently living more on the “support” side of the equation than the “science” one. Listed at a modest ₹30.9 with a market cap of ₹456 crore, this is a company that’s been on more mood swings than the Sensex during election week.

With a P/E of 114, Book Value ₹1.73, and an ROE of a jaw-dropping 644% (don’t celebrate yet — it’s a mathematical illusion of low equity), this stock has turned heads for reasons both financial and fictional. The promoter holding is now just 5.19%, down from 53% earlier this year — yes, they basically left the WhatsApp group.

Recent board meeting notes from October 2025 scream:
Loss ₹697.36 million, auditors resigned, going concern doubts, and tax litigations ₹720.99 million. If this were a Bollywood movie, the climax would feature an auditor throwing balance sheets off a cliff while shouting, “Yeh company chal nahi sakti!”

And yet — and this is the punchline — the stock has soared 255% in 6 months and 208% in 3 months. Because in the Indian stock market, logic took a sabbatical.

2. Introduction

If there were a reality show called “Bigg Boss: Corporate Edition”, Take Solutions would be the wildcard entry — a perfect mix of medical jargon, management drama, and mysterious promoter exits.

Founded in 2000, this Chennai-based company once wore the crown of “clinical data science innovation.” Today, it’s more like a survivor of financial trials than clinical ones.

After selling its prime subsidiaries in FY23–FY24, it’s been trying to rebuild with whatever’s left in the lab fridge. Once upon a time, TAKE Global Holdings and Ecron Acunova ran advanced bioavailability and pharmacovigilance studies. Now, even the term “availability” sounds ironic.

Meanwhile, its Singapore parent, Take Solutions Pte Ltd, divested completely in September 2025. That’s right — the once 52.9% promoter is now at 0% holding, having sold its shares off-market faster than you can say “exit strategy.”

Yet investors, in a rare display of optimism (or masochism), have pushed the price from ₹6.5 to ₹30+, hoping for a resurrection. Maybe they believe in miracles, maybe they just love volatility.

3. Business Model – WTF Do They Even Do?

At its core, Take Solutions Ltd operates in Life Sciences and Clinical Research — specifically, services like clinical trials, regulatory filings, pharmacovigilance, and bioequivalence testing. Basically, it helps pharma companies ensure that generics work as well as the originals — the “Pepsi vs. Coke” of the medical world.

The company’s flagship subsidiary Ecron Acunova Ltd conducts bioavailability (BA) and bioequivalence (BE) studies, focusing on Phase I trials involving healthy volunteers. Recently, they’ve expanded to 150 beds in Manipal, investing ₹9 crore of the planned ₹12 crore. Because nothing says “commitment” like testing drugs on volunteers while your balance sheet flatlines.

On the digital front, TAKE once claimed to “enable cloud-driven patient-centric solutions” — translation: “We make healthcare sound like an IT startup.” Their Digital Healthcare wing works on AI-based diagnostics and automated medical management, though recent revenues suggest that AI might be the only thing still working.

Post-divestment, the group’s scale has shrunk drastically. Gone are the global arms like Acunova Life Science (USA) and Navitas Thailand. What remains is a leaner, India-focused structure hanging on through Ecron Acunova. Think of it as the pharmaceutical version of a once-famous rock band now performing at local pubs.

4. Financials Overview

Let’s lock to Quarterly Results — September 2025 being the latest available consolidated data.